Suppr超能文献

培养的人系膜细胞对细胞外基质的降解是由纤溶酶原激活物/纤溶酶/基质金属蛋白酶-2级联反应介导的。

ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.

作者信息

Baricos W H, Cortez S L, el-Dahr S S, Schnaper H W

机构信息

Department of Biochemistry, Tulane Medical School, New Orleans, Louisiana, USA.

出版信息

Kidney Int. 1995 Apr;47(4):1039-47. doi: 10.1038/ki.1995.150.

Abstract

We examined the role of the plasminogen activator/plasmin system in extracellular matrix (ECM) degradation by human mesangial cells cultured on thin films of 125I-labeled ECM (Matrigel). ECM degradation (release of 125I into the medium) was dependent on exogenous plasminogen, proportional to the number of mesangial cells and amount of plasminogen added, and coincident with the appearance of plasmin in the medium. ECM degradation was completely blocked (P < 0.001) by two plasmin inhibitors, alpha-2-antiplasmin (40 micrograms/ml) and aprotinin (216 KIU/ml), and partially reduced (-33 +/- 1.8%, P < 0.01) by TIMP-1 (40 micrograms/ml), a specific inhibitor of matrix metalloproteinases. Zymography of medium obtained from cells cultured in the absence of plasminogen revealed the presence of latent matrix metalloproteinase-2 (MMP-2) which was converted to a lower molecular weight, active form in the presence of mesangial cells and plasminogen. Northern analysis of poly A+RNA prepared from cultured human mesangial cells revealed mRNA for tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and uPA receptor (uPAR). The presence of uPA protein in medium obtained from cultured human mesangial cells was demonstrated by Western blotting and ELISA which revealed a large molar excess of PAI-1 (1.2 +/- 0.1 x 10(-9) M) over uPA (1.2 +/- 0.1 x 10(-12) M) and tPA (0.19 +/- 0.04 x 10(-9) M). ECM degradation was reduced by a monoclonal antibody (MAb) against human tPA (-54 +/- 8.6%) or human uPA (-39 +/- 5.2%) compared to cells treated with identical amounts of non-specific monoclonal IgG (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们研究了纤溶酶原激活物/纤溶酶系统在人系膜细胞降解细胞外基质(ECM)中的作用,这些细胞培养于125I标记的ECM(基质胶)薄膜上。ECM降解(125I释放到培养基中)依赖于外源性纤溶酶原,与系膜细胞数量及添加的纤溶酶原量成正比,且与培养基中纤溶酶的出现同步。两种纤溶酶抑制剂,α-2-抗纤溶酶(40微克/毫升)和抑肽酶(216 KIU/毫升)可完全阻断ECM降解(P<0.001),基质金属蛋白酶特异性抑制剂TIMP-1(40微克/毫升)可部分降低ECM降解(-33±1.8%,P<0.01)。对在无纤溶酶原条件下培养的细胞的培养基进行酶谱分析,发现存在潜在的基质金属蛋白酶-2(MMP-2),在系膜细胞和纤溶酶原存在的情况下,其可转化为低分子量的活性形式。对培养的人系膜细胞制备的多聚A+RNA进行Northern分析,发现有组织型纤溶酶原激活物(tPA)、尿激酶型纤溶酶原激活物(uPA)、纤溶酶原激活物抑制剂-1(PAI-1)和uPA受体(uPAR)的mRNA。通过蛋白质印迹法和酶联免疫吸附测定法证实,培养的人系膜细胞的培养基中存在uPA蛋白,结果显示PAI-1(1.2±0.1×10-9M)在摩尔数上大大超过uPA(1.2±0.1×10-12M)和tPA(0.19±0.04×10-9M)。与用等量非特异性单克隆IgG处理的细胞相比,抗人tPA单克隆抗体(MAb)(-54±8.6%)或抗人uPA单克隆抗体(-39±5.2%)可降低ECM降解(P<0.01)。(摘要截短于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验